share_log

Intelligent Bio Solutions | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Lind Global Fund II LP(3.4%),Lind Global Partners II LLC(3.4%), etc.

Intelligent Bio Solutions | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Lind Global Fund II LP(3.4%),Lind Global Partners II LLC(3.4%), etc.

Intelligent Bio Solutions | SC 13G/A:超過5%持股股東披露文件(修正)-Lind Global Fund II LP(3.4%),Lind Global Partners II LLC(3.4%)等
美股SEC公告 ·  2024/11/14 19:22

牛牛AI助理已提取核心訊息

On September 30, 2024, Intelligent Bio Solutions Inc. was the subject of a Schedule 13G filing with the United States Securities and Exchange Commission, indicating a change in ownership by certain entities and individuals. The filing was made by Lind Global Fund II LP, Lind Global Partners II LLC, and Jeff Easton, collectively referred to as the Reporting Persons. Each of the Reporting Persons reported beneficial ownership of 151,515 warrants to purchase common stock of Intelligent Bio Solutions, representing 3.4% of the company's class of securities. The warrants grant sole voting and dispositive power over the shares they may be converted into. The filing indicates that the ownership does not aim to change or influence the control of Intelligent Bio Solutions. The principal business office for the Reporting Persons is located at 444 Madison Ave, Floor 41, New York, NY 10022. The filing, which includes a joint filing agreement, was signed on November 14, 2024, by Jeff Easton, who is the managing member of Lind Global Partners II LLC and associated with Lind Global Fund II LP.
On September 30, 2024, Intelligent Bio Solutions Inc. was the subject of a Schedule 13G filing with the United States Securities and Exchange Commission, indicating a change in ownership by certain entities and individuals. The filing was made by Lind Global Fund II LP, Lind Global Partners II LLC, and Jeff Easton, collectively referred to as the Reporting Persons. Each of the Reporting Persons reported beneficial ownership of 151,515 warrants to purchase common stock of Intelligent Bio Solutions, representing 3.4% of the company's class of securities. The warrants grant sole voting and dispositive power over the shares they may be converted into. The filing indicates that the ownership does not aim to change or influence the control of Intelligent Bio Solutions. The principal business office for the Reporting Persons is located at 444 Madison Ave, Floor 41, New York, NY 10022. The filing, which includes a joint filing agreement, was signed on November 14, 2024, by Jeff Easton, who is the managing member of Lind Global Partners II LLC and associated with Lind Global Fund II LP.
在2024年9月30日,Intelligent Bio Solutions Inc. 向美國證券交易委員會提交了13G表格,表明某些實體和個人的持股變化。該文件由Lind Global Fund II LP、Lind Global Partners II LLC和Jeff Easton共同提交,被稱爲報告人。每位報告人均報告擁有151,515個可以購買Intelligent Bio Solutions普通股的warrants,佔公司證券類別的3.4%。這些warrants授予對其轉換爲股份的投票和處置權。該文件表明,所有權並不旨在改變或影響Intelligent Bio Solutions的控...展開全部
在2024年9月30日,Intelligent Bio Solutions Inc. 向美國證券交易委員會提交了13G表格,表明某些實體和個人的持股變化。該文件由Lind Global Fund II LP、Lind Global Partners II LLC和Jeff Easton共同提交,被稱爲報告人。每位報告人均報告擁有151,515個可以購買Intelligent Bio Solutions普通股的warrants,佔公司證券類別的3.4%。這些warrants授予對其轉換爲股份的投票和處置權。該文件表明,所有權並不旨在改變或影響Intelligent Bio Solutions的控制權。報告人的主要業務辦公室位於紐約市麥迪遜大道444號,41層,郵政編碼10022。該文件,包括一份聯合提交協議,於2024年11月14日由Jeff Easton簽署,他是Lind Global Partners II LLC的管理成員,並與Lind Global Fund II LP相關聯。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。